Abstract: The present invention relates to high drug load pharmaceutical compositions comprising eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.

Abstract: Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.

Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.

Abstract: The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX® capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.

Abstract: The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX® capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives.

Abstract: The present invention relates to pharmaceutical composition of Cinacalcet or a pharmaceutically acceptable salt thereof comprising diluents, binders and lubricants, wherein said composition is substantially free of disintegrant. It further relates to process for preparing such compositions.

Abstract: The present invention relates to a solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form of the present invention is free of non-pareil seeds. The invention also relates to a process for the preparation of a pharmaceutical composition comprising an effective amount of Tizanidine wherein, the dosage form is free of non-pareil seeds.

Abstract: The present invention relates to pharmaceutical composition of Cinacalcet or a pharmaceutically acceptable salt thereof comprising diluents, binders and lubricants, wherein said composition is substantially free of disintegrant. It further relates to process for preparing such compositions.

Abstract: The present invention is directed towards the preparation of extended release Alprazolam formulation. The formulation thus obtained provides an efficient mode of delivery of Alprazolam in a continuous manner.

Abstract: The present invention is directed towards the preparation of extended release Alprazolam formulation. The formulation thus obtained provides an efficient mode of delivery of Alprazolam in a continuous manner.